Lung Kee (Bermuda) Holdings Limited (0255) AI Stock Analysis

• Market Cap: HK$814.86M
• Dividend Yield: 6.76%
• Average Volume (3M): 121.96K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.38
• Revenue Growth: 7.17%
• EPS Growth: 81.17%
• Country: HK
• Employees: 3,000
• Sector: Industrials
• Sector Strength: 92
• Industry: Manufacturing - Metal Fabrication
• EPS (TTM): -0.02
• Shares Outstanding: 631,677,300
• 10 Day Avg. Volume: 171,282
• 30 Day Avg. Volume: 121,963
• PEG Ratio: -0.83
• Price to Book (P/B): 0.53
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 4.67
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 49 Neutral
• Price Target: ―

Lung Kee (Bermuda) Holdings Limited shows significant financial challenges with declining revenues and profitability, as evidenced by negative net income and EBIT, which weigh heavily on the stock score. Despite this, the company's strong balance sheet and improved cash flow position provide some stability. The technical analysis indicates a neutral trend with potential for consolidation, while the negative P/E ratio poses valuation concerns. The high dividend yield offers a potential attraction for income-seeking investors, but overall, the stock faces substantial hurdles to be considered a strong buy.

Lung Kee (Bermuda) Holdings Limited Business Overview & Revenue Model

Company Description

Lung Kee (Bermuda) Holdings Limited is a leading investment holding company primarily engaged in the manufacturing and distribution of mold bases and related products. The company operates within the industrial manufacturing sector, providing essential components for the production of diverse products across various industries, including automotive, electronics, and consumer goods. Lung Kee maintains a prominent position in the market through its extensive network and state-of-the-art manufacturing facilities.

How the Company Makes Money

Lung Kee (Bermuda) Holdings Limited generates revenue predominantly through the manufacturing and sale of high-quality mold bases, which are crucial components in the molding and tooling industry. The company earns income by supplying these products to a wide range of manufacturers who use them to produce finished goods. Additionally, Lung Kee's revenue model is supported by its ability to leverage economies of scale through its expansive manufacturing operations and strategic partnerships with key industry players, ensuring a steady demand for its products. The company also benefits from its strong distribution network, which facilitates efficient product delivery to its global client base, further enhancing its revenue streams.

Lung Kee (Bermuda) Holdings Limited Financial Statement Overview

Summary

Lung Kee (Bermuda) Holdings Limited faces challenges with declining revenues and profitability, as evidenced by negative net income and EBIT. However, the company maintains a robust balance sheet with strong equity and manageable debt levels. The cash flow position has improved, suggesting better cash management and potential for recovery. The company needs to address operational inefficiencies to enhance profitability while leveraging its financial stability for future growth.

Income Statement

The company experienced a decline in revenue over the past years, with a noticeable drop from 2020 to 2023. The gross profit margin improved significantly in 2024 due to a substantial increase in gross profit, despite a decrease in revenue. However, the negative EBIT and net income in recent years indicate operational challenges affecting profitability. The net profit margin is negative, highlighting profitability issues.

Balance Sheet

The company maintains a strong equity base, with a high equity ratio and low debt-to-equity ratio, indicating financial stability. Despite a decrease in total assets, the decrease in liabilities suggests improved leverage management. The return on equity has turned negative due to recent net losses, which warrants attention.

Cash Flow

The cash flow statements show a positive trend in free cash flow, recovering from negative figures in previous years. The operating cash flow to net income ratio is strong, indicating efficient cash generation relative to earnings. The company shows improvement in managing capital expenditures, contributing to a positive free cash flow.

Breakdown
Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
1.55B	1.45B	1.60B	2.27B	2.06B
	Gross Profit
951.69M	263.90M	398.00M	777.07M	653.19M
	EBIT
-26.00M	-124.07M	3.87M	289.20M	190.18M
	EBITDA
148.58M	56.87M	180.74M	472.05M	367.38M
	Net Income Common Stockholders
-13.67M	-72.43M	15.81M	227.84M	181.08M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
546.65M	428.76M	536.64M	833.59M	918.62M
	Total Assets
1.97B	2.09B	2.30B	2.75B	2.75B
	Total Debt
7.83M	6.57M	9.56M	9.02M	14.29M
	Net Debt
-538.82M	-422.19M	-527.08M	-824.56M	-904.33M
	Total Liabilities
298.08M	294.22M	314.90M	474.46M	471.25M
	Stockholders Equity
1.67B	1.80B	1.99B	2.27B	2.27B
Cash Flow		Free Cash Flow
190.82M	-35.72M	-93.17M	168.61M	255.22M
	Operating Cash Flow
226.34M	77.21M	89.17M	369.94M	368.26M
	Investing Cash Flow
-24.35M	-98.07M	-170.05M	-193.03M	-107.73M
	Financing Cash Flow
-67.33M	-73.86M	-168.90M	-277.76M	-139.41M

Lung Kee (Bermuda) Holdings Limited Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 1.48
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:0255, the sentiment is Positive. The current price of 1.48 is above the 20-day moving average (MA) of 1.25, above the 50-day MA of 1.21, and above the 200-day MA of 1.07, indicating a bullish trend. The MACD of 0.03 indicates Negative momentum. The RSI at 59.07 is Neutral, neither overbought nor oversold. The STOCH value of -74.07 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:0255.

Lung Kee (Bermuda) Holdings Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
1038	71 Outperform	$124.68B	16.21	6.62%	4.93%	-16.64%	1.10%
Sector *	64 Neutral	$4.39B	11.81	5.20%	249.38%	3.96%	-12.36%
1036	51 Neutral	HK$568.71M	―	-1.19%	4.11%	111.64%	-282.42%
0237	50 Neutral	HK$769.50M	―	-1.81%	4.03%	8.19%	32.85%
0255	49 Neutral	HK$814.86M	―	-0.79%	6.76%	7.17%	81.17%
0581	47 Neutral	$4.73B	29.26	0.67%	―	-8.84%	―

Lung Kee (Bermuda) Holdings Limited Corporate Events

Lung Kee Holdings Announces Successful AGM Resolutions

Lung Kee (Bermuda) Holdings Limited announced that all resolutions were passed at its annual general meeting held on May 19, 2025. These resolutions included the approval of financial statements, the declaration of dividends, re-election of directors, and granting mandates for share issuance and buyback. The successful passing of these resolutions indicates strong shareholder support and positions the company for continued operational and strategic initiatives.

Lung Kee Group Holdings Announces 2025 AGM and Key Resolutions

Lung Kee Group Holdings Limited has announced its upcoming annual general meeting scheduled for May 19, 2025, in Hong Kong. Key agenda items include the approval of the company’s audited financial statements for 2024, the declaration of a final and special dividend, and the re-election of directors. Additionally, the meeting will address the authorization for the board to appoint directors and fix their remuneration, as well as the re-appointment of the company’s auditor. A special resolution will also be considered to allow the directors to issue additional shares, subject to certain conditions, which could impact the company’s capital structure and shareholder value.

Lung Kee (Bermuda) Holdings Announces Final Dividend for 2024

Lung Kee (Bermuda) Holdings Limited has announced a final ordinary cash dividend of HKD 0.06 per share for the financial year ending December 31, 2024. This announcement, made on March 21, 2025, outlines key dates including the ex-dividend date on May 23, 2025, and the payment date on June 9, 2025. The approval from shareholders is expected on May 19, 2025. This dividend declaration reflects the company’s ongoing commitment to returning value to its shareholders and may influence investor sentiment positively.

Lung Kee Announces Final Special Dividend for 2024

Lung Kee (Bermuda) Holdings Limited has announced a final special dividend of HKD 0.12 per share for the financial year ending December 31, 2024. The dividend will be paid on June 9, 2025, following shareholder approval on May 19, 2025. This announcement reflects the company’s financial strategy and commitment to returning value to its shareholders, potentially impacting its market positioning positively.

Lung Kee Group Reports Improved Financial Results for 2024

Lung Kee Group Holdings Limited reported its audited consolidated results for the year ending December 31, 2024, showing a revenue increase to HK$1,553,244,000 from HK$1,449,340,000 in 2023. Despite the revenue growth, the company experienced a loss of HK$13,673,000 for the year, an improvement from the previous year’s loss of HK$72,431,000. The total comprehensive expense for the year was HK$62,487,000, compared to HK$118,457,000 in 2023, indicating a reduction in overall expenses. The results reflect challenges in the market, including exchange rate impacts and operational costs, but also highlight the company’s efforts in reducing losses and managing expenses.